+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bile Duct Cancer Drug Market by Type, Gemcitabine, Cisplatin, Capecitabine, Oxaliplatin, and Others and by Application: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017-2024

  • ID: 4853908
  • Report
  • January 2019
  • Region: Global
  • 110 pages
  • Zion Market Research
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now

The report covers a forecast and an analysis of the bile duct cancer drug market on a global and regional level. The study provides historical data for 2015, 2016, and 2017 along with a forecast from 2018 to 2024 based on revenue (USD million). The study includes drivers and restraints for the bile duct cancer drug market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the bile duct cancer drug market on a global level.

In order to give the users of this report a comprehensive view of the bile duct cancer drug market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis. 

The study provides a decisive view on the bile duct cancer drug market by segmenting the market based on type, application, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024.

By type, bile duct cancer drug market is segmented as 5-fluorouracil (5-FU), capecitabine, gemcitabine, oxaliplatin, cisplatin, and other. Based on application, bile duct cancer drug market has been segmented into hospitals, clinics, and others. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further divided into major countries including the U.S., Germany, Italy, France, UK, China, Japan, India, and Brazil.

Some key players of the bile duct cancer drug market include Delcath Systems Inc., Accord Healthcare, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Pfizer Inc., Eli Lilly and Company, Mylan N.V, Fresenius Kabi AG, Intercept Pharmaceuticals, Inc., and Celgene Corporation, among others.

This report segments the global bile duct cancer drug market into:

Global Bile Duct Cancer Drug Market: By Product

  • 5-fluorouracil (5-FU)
  • Gemcitabine
  • Cisplatin
  • Capecitabine
  • Oxaliplatin
  • Others

Global Bile Duct Cancer Drug Market: By Application

  • Hospitals
  • Clinics
  • Others

Global Bile Duct Cancer Drug Market: By Region

  • North America
  • The U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa
Note: Product cover images may vary from those shown
2 of 2
  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  • Chapter 2. Executive Summary
    • 2.1. Global Bile Duct Cancer Drug Market, 2017 - 2024 (USD Million)
    • 2.2. Global Bile Duct Cancer Drug Market: Snapshot
  • Chapter 3. Bile Duct Cancer Drug Market - Industry Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Bile Duct Cancer Drug Market drivers: Impact analysis
      • 3.2.2. The worldwide growing prevalence of bile duct cancer
      • 3.2.3. Technological improvement in the health care sector
    • 3.3. Market Restraints
      • 3.3.1. High-cost cancer treatment in the developed region as well as the high cost associated with clinical trials
      • 3.3.2. long duration in approvals of drug
    • 3.4. Opportunities
      • 3.4.1. An increasing prevalence of cancer and the need for combination therapies
    • 3.5. Porter's Five Forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. The threat from new entrants
      • 3.5.4. The threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by Type
      • 3.6.2. Market attractiveness analysis, by Application
      • 3.6.3. Market attractiveness analysis, by Region
  • Chapter 4. Global Bile Duct Cancer Drug Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Bile Duct Cancer Drug Market: company market share, 2017
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations, and Joint Ventures
      • 4.2.4. Research and Development, and Regional Expansion
  • Chapter 5. Global Bile Duct Cancer Drug Market - Type Analysis
    • 5.1. Global Bile Duct Cancer Drug Market: Type overview
      • 5.1.1. Global Bile Duct Cancer Drug Market revenue share, by Type, 2017 and 2024(USD Million)
    • 5.2. 5-fluorouracil (5-FU)
      • 5.2.1. Global 5-fluorouracil (5-FU)market, 2017 - 2024(USD Million)
    • 5.3. Gemcitabine
      • 5.3.1. Global Gemcitabine market, 2017 - 2024(USD Million)
    • 5.4. Cisplatin
      • 5.4.1. Global Cisplatin market, 2017 - 2024(USD Million)
    • 5.5. Capecitabine
      • 5.5.1. Global Capecitabine market, 2017 - 2024(USD Million)
    • 5.6. Oxaliplatin
      • 5.6.1. Global Oxaliplatin market, 2017 - 2024(USD Million)
    • 5.7. Others
      • 5.7.1. Global Others market, 2017 - 2024(USD Million)
  • Chapter 6. Global Bile Duct Cancer Drug Market - Application Analysis
    • 6.1. Global Bile Duct Cancer Drug Market: Application overview
      • 6.1.1. Global Bile Duct Cancer Drug Market revenue share, by Application, 2017 and 2024(USD Million)
    • 6.2. Hospitals
      • 6.2.1. Global Bile Duct Cancer Drug Market for Hospitals, 2017 - 2024(USD Million)
    • 6.3. Clinics
      • 6.3.1. Global Bile Duct Cancer Drug Market for Clinics, 2017 - 2024(USD Million)
    • 6.4. Others
      • 6.4.1. Global Bile Duct Cancer Drug Market for Others, 2017 - 2024(USD Million)
  • Chapter 7. Global Bile Duct Cancer Drug Market - Regional Analysis
    • 7.1. Global Bile Duct Cancer Drug Market: Regional overview
      • 7.1.1. Global Bile Duct Cancer Drug Market revenue share, by Region, 2015 and 2024
    • 7.2. North America
      • 7.2.1. North America Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
      • 7.2.2. North America Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
        • 7.2.2.1. The U.S.
          • 7.2.2.1.1. The U.S. Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
          • 7.2.2.1.2. The U.S. Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
        • 7.2.2.2. Rest of North America
          • 7.2.2.2.1. Rest of North America Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
          • 7.2.2.2.2. Rest of North America Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
    • 7.3. Europe
      • 7.3.1. Europe Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
      • 7.3.2. Europe Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.3.3. Germany
        • 7.3.3.1. Germany Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.3.3.2. Germany Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.3.4. U.K.
        • 7.3.4.1. U.K. Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.3.4.2. U.K. Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.3.5. France
        • 7.3.5.1. France Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.3.5.2. France Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.3.6. Rest of Europe
        • 7.3.6.1. Rest of Europe Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.3.6.2. Rest of Europe Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
      • 7.4.2. Asia Pacific Bile Duct Cancer Drug Market revenue, Application, 2017 - 2024(USD Million)
      • 7.4.3. China
        • 7.4.3.1. China Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.4.3.2. China Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.4.4. Japan
        • 7.4.4.1. Japan Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.4.4.2. Japan Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.4.5. India
        • 7.4.5.1. India Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.4.5.2. India Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.4.6. Rest of Asia Pacific
        • 7.4.6.1. Rest of Asia Pacific Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.4.6.2. Rest of Asia Pacific Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
    • 7.5. Latin America
      • 7.5.1. Latin America Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
      • 7.5.2. Latin America Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.5.3. Brazil
        • 7.5.3.1. Brazil Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.5.3.2. Brazil Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
      • 7.5.4. Rest of Latin America
        • 7.5.4.1. Rest of Latin America Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
        • 7.5.4.2. Rest of Latin America Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
    • 7.6. The Middle East and Africa
      • 7.6.1. The Middle East and Africa Bile Duct Cancer Drug Market revenue, by Type, 2017 - 2024(USD Million)
      • 7.6.2. The Middle East and Africa Bile Duct Cancer Drug Market revenue, by Application, 2017 - 2024(USD Million)
  • Chapter 8. Company Profile
    • 8.1. Delcath Systems Inc.
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Therapy portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. Accord Healthcare
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Therapy portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. F. Hoffmann-La Roche Ltd.
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Therapy portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. Pfizer Inc.
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Therapy portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
    • 8.5. Teva Pharmaceutical Industries Ltd.
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Therapy portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Bristol-Myers Squibb Company
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Therapy portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. Eli Lilly and Company
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Therapy portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
    • 8.8. Mylan N.V.
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Therapy portfolio
      • 8.8.4. Business strategy
      • 8.8.5. Recent developments
    • 8.9. Fresenius Kabi AG
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Therapy portfolio
      • 8.9.4. Business strategy
      • 8.9.5. Recent developments
    • 8.10. Intercept Pharmaceuticals, Inc.
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Therapy portfolio
      • 8.10.4. Business strategy
      • 8.10.5. Recent developments
Note: Product cover images may vary from those shown
Adroll
adroll